vs
Side-by-side financial comparison of AXT INC (AXTI) and DELCATH SYSTEMS, INC. (DCTH). Click either name above to swap in a different company.
AXT INC is the larger business by last-quarter revenue ($26.9M vs $20.7M, roughly 1.3× DELCATH SYSTEMS, INC.). On growth, AXT INC posted the faster year-over-year revenue change (39.1% vs 37.3%). Over the past eight quarters, DELCATH SYSTEMS, INC.'s revenue compounded faster (157.0% CAGR vs -1.8%).
AXT Inc designs, manufactures and sells high-performance compound semiconductor substrates, including gallium arsenide, indium phosphide and germanium wafers. Its products power optoelectronic and radio frequency devices for global communications, consumer electronics and industrial end markets.
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in th...
AXTI vs DCTH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.9M | $20.7M |
| Net Profit | — | $-1.9M |
| Gross Margin | 29.6% | 85.5% |
| Operating Margin | 64.5% | -10.5% |
| Net Margin | — | -9.1% |
| Revenue YoY | 39.1% | 37.3% |
| Net Profit YoY | — | 44.2% |
| EPS (diluted) | — | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $26.9M | — | ||
| Q4 25 | $23.0M | $20.7M | ||
| Q3 25 | $28.0M | $20.6M | ||
| Q2 25 | $18.0M | $24.2M | ||
| Q1 25 | $19.4M | $19.8M | ||
| Q4 24 | $25.1M | $15.1M | ||
| Q3 24 | $23.6M | $11.2M | ||
| Q2 24 | $27.9M | $7.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-3.5M | $-1.9M | ||
| Q3 25 | $-1.9M | $830.0K | ||
| Q2 25 | $-7.0M | $2.7M | ||
| Q1 25 | $-8.8M | $1.1M | ||
| Q4 24 | $-5.1M | $-3.4M | ||
| Q3 24 | $-2.9M | $1.9M | ||
| Q2 24 | $-1.5M | $-13.7M |
| Q1 26 | 29.6% | — | ||
| Q4 25 | 20.9% | 85.5% | ||
| Q3 25 | 22.3% | 87.2% | ||
| Q2 25 | 8.0% | 86.3% | ||
| Q1 25 | -6.4% | 85.6% | ||
| Q4 24 | 17.6% | 85.9% | ||
| Q3 24 | 24.0% | 85.4% | ||
| Q2 24 | 27.4% | 80.4% |
| Q1 26 | 64.5% | — | ||
| Q4 25 | -16.6% | -10.5% | ||
| Q3 25 | -4.0% | -1.9% | ||
| Q2 25 | -37.5% | 10.7% | ||
| Q1 25 | -53.1% | 3.2% | ||
| Q4 24 | -24.6% | 20.1% | ||
| Q3 24 | -14.4% | -11.2% | ||
| Q2 24 | -6.8% | -50.4% |
| Q1 26 | — | — | ||
| Q4 25 | -15.4% | -9.1% | ||
| Q3 25 | -6.8% | 4.0% | ||
| Q2 25 | -39.0% | 11.2% | ||
| Q1 25 | -45.5% | 5.4% | ||
| Q4 24 | -20.3% | -22.5% | ||
| Q3 24 | -12.4% | 16.6% | ||
| Q2 24 | -5.4% | -176.9% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.09 | $-0.05 | ||
| Q3 25 | $-0.04 | $0.02 | ||
| Q2 25 | $-0.16 | $0.07 | ||
| Q1 25 | $-0.20 | $0.03 | ||
| Q4 24 | $-0.11 | $-0.06 | ||
| Q3 24 | $-0.07 | $0.06 | ||
| Q2 24 | $-0.04 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $107.1M | $43.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $298.4M | $111.2M |
| Total Assets | $444.6M | $123.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $107.1M | — | ||
| Q4 25 | $120.3M | $43.5M | ||
| Q3 25 | $23.1M | $41.8M | ||
| Q2 25 | $27.0M | $34.4M | ||
| Q1 25 | $31.6M | $12.8M | ||
| Q4 24 | $22.8M | $32.4M | ||
| Q3 24 | $24.9M | $8.3M | ||
| Q2 24 | $29.5M | $14.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $4.5M |
| Q1 26 | $298.4M | — | ||
| Q4 25 | $273.3M | $111.2M | ||
| Q3 25 | $179.1M | $114.8M | ||
| Q2 25 | $179.7M | $105.0M | ||
| Q1 25 | $185.0M | $80.2M | ||
| Q4 24 | $192.8M | $68.7M | ||
| Q3 24 | $200.7M | $8.6M | ||
| Q2 24 | $199.7M | $4.2M |
| Q1 26 | $444.6M | — | ||
| Q4 25 | $433.8M | $123.6M | ||
| Q3 25 | $334.0M | $124.3M | ||
| Q2 25 | $329.0M | $116.9M | ||
| Q1 25 | $333.5M | $87.3M | ||
| Q4 24 | $339.3M | $76.6M | ||
| Q3 24 | $355.6M | $31.7M | ||
| Q2 24 | $349.4M | $33.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $8.2M |
| Free Cash FlowOCF − Capex | — | $7.7M |
| FCF MarginFCF / Revenue | — | 37.1% |
| Capex IntensityCapex / Revenue | — | 2.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $21.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.3M | $8.2M | ||
| Q3 25 | $-9.2M | $4.8M | ||
| Q2 25 | $-4.6M | $7.3M | ||
| Q1 25 | $-3.3M | $2.2M | ||
| Q4 24 | $1.3M | $-1.0M | ||
| Q3 24 | $-5.4M | $-3.6M | ||
| Q2 24 | $843.0K | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | $1.3M | $7.7M | ||
| Q3 25 | $-11.3M | $4.3M | ||
| Q2 25 | $-4.9M | $6.9M | ||
| Q1 25 | $-3.9M | $2.1M | ||
| Q4 24 | $1.1M | $-1.2M | ||
| Q3 24 | $-6.4M | $-3.9M | ||
| Q2 24 | $572.0K | $-4.6M |
| Q1 26 | — | — | ||
| Q4 25 | 5.5% | 37.1% | ||
| Q3 25 | -40.5% | 21.0% | ||
| Q2 25 | -27.0% | 28.5% | ||
| Q1 25 | -19.9% | 10.4% | ||
| Q4 24 | 4.4% | -8.2% | ||
| Q3 24 | -26.9% | -34.4% | ||
| Q2 24 | 2.0% | -58.6% |
| Q1 26 | — | — | ||
| Q4 25 | 13.2% | 2.7% | ||
| Q3 25 | 7.8% | 2.2% | ||
| Q2 25 | 1.6% | 1.6% | ||
| Q1 25 | 2.6% | 0.7% | ||
| Q4 24 | 0.7% | 1.5% | ||
| Q3 24 | 4.0% | 1.9% | ||
| Q2 24 | 1.0% | 1.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 5.75× | ||
| Q2 25 | — | 2.70× | ||
| Q1 25 | — | 2.06× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXTI
Segment breakdown not available.
DCTH
| HEPZATOKIT | $19.1M | 92% |
| CHEMOSAT | $1.7M | 8% |
